INTENSITY THERAPEUTICS, INC.
About INTENSITY THERAPEUTICS, INC.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$11.6M
- Total assets
- $14.1M
- Market cap
- $10.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.0M
- Operating income
- -$12.0M
- Income tax
- $0
- Net income
- -$11.6M
- EPS (basic)
- $-8.56
- EPS (diluted)
- $-8.56
Balance sheet
- Total assets
- $14.1M
- Current assets
- $12.7M
- Total liabilities
- $2.2M
- Current liabilities
- $2.1M
- Shareholders’ equity
- $11.9M
Cash flow
- Operating cash flow
- -$9.2M
- Investing cash flow
- -$9.3M
- Financing cash flow
- $18.6M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $10.2M
- EPS (diluted)
- $-8.56
- Shares outstanding
- 2.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 30, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.6M.
- Trading 89% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review INTENSITY THERAPEUTICS, INC..
Write a review
News about INTENSITY THERAPEUTICS, INC.
News & sentiment via Polygon.io
